Aadi Bioscience
Pacific Palisades
About Aadi Bioscience
Aadi Bioscience, Inc. is a biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi’s primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. Aadi’s initial focus is the treatment of an ultra-rare cancer PEComa, also known as perivascular epithelioid cell tumor.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $350.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2025)
- Ticker: nasdaq:AADI
- Website: aadibio.com
- Phone: (424) 744-8055
Industries & Categories
Biopharma, Biotechnology, Life Science, Oncology
Social Profiles
Canonical: https://fsome.com/organization/aadi-bioscience-115489 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.